S
Sarah Zohar
Researcher at University of Paris
Publications - 123
Citations - 3558
Sarah Zohar is an academic researcher from University of Paris. The author has contributed to research in topics: Clinical trial & Population. The author has an hindex of 31, co-authored 117 publications receiving 2954 citations. Previous affiliations of Sarah Zohar include French Institute for Research in Computer Science and Automation & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Pierre-François Dequin,Pierre-François Dequin,N Heming,Ferhat Meziani,Gaëtan Plantefève,Guillaume Voiriot,Julio Badie,Bruno François,Bruno François,Cécile Aubron,Jean-Damien Ricard,Stephan Ehrmann,Stephan Ehrmann,Youenn Jouan,Youenn Jouan,Antoine Guillon,Antoine Guillon,Marie Leclerc,Carine Coffre,Hélène Bourgoin,Céline Lengellé,Caroline Caille-Fénérol,Elsa Tavernier,Sarah Zohar,Bruno Giraudeau,Bruno Giraudeau,Djillali Annane,Amélie Le Gouge +27 more
TL;DR: Low-dose hydrocortisone, compared with placebo, did not significantly reduce treatment failure at day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure, and this study was stopped early.
Journal ArticleDOI
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
Alexandre Carpentier,Florence Laigle-Donadey,Sarah Zohar,Laurent Capelle,Anthony Behin,Annick Tibi,Nadine Martin-Duverneuil,Marc Sanson,Lucette Lacomblez,Sophie Taillibert,Louis Puybasset,Rémy Van Effenterre,Jean-Yves Delattre,Antoine F. Carpentier +13 more
TL;DR: In conclusion, CpG-28 was well tolerated at doses up to 20 mg per injection in patients with recurrent glioblastoma, and main side effects were limited to transient worsening of neurological condition and fever.
Journal ArticleDOI
Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO) : an open-label, dose finding, and feasibility phase 1/2 trial
Ronit M. Pressler,Geraldine B. Boylan,Neil Marlow,Mats Blennow,Catherine Chiron,Catherine Chiron,J. Helen Cross,Linda S. de Vries,Boubou Hallberg,Lena Hellström-Westas,Vincent Jullien,Vincent Jullien,Vicki Livingstone,Barry Mangum,Brendan P. Murphy,Deirdre M. Murray,Gérard Pons,Gérard Pons,Janet M. Rennie,Renate Swarte,Mona C. Toet,Sampsa Vanhatalo,Sarah Zohar +22 more
TL;DR: The findings suggest that bumetanide as an add-on to phenobarbital does not improve seizure control in newborn infants who have hypoxic ischaemic encephalopathy and might increase the risk of hearing loss, highlighting the risks associated with the off-label use of drugs in newborn babies before safety assessment in controlled trials.
Journal ArticleDOI
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study
Alexandre Carpentier,Philippe Metellus,Renata Ursu,Sarah Zohar,Francois Lafitte,Maryline Barrie,Yuxia Meng,Margaretha Richard,Christophe Parizot,Florence Laigle-Donadey,Guy Gorochov,Dimitri Psimaras,Marc Sanson,Annick Tibi,Olivier Chinot,Antoine F. Carpentier +15 more
TL;DR: Despite a few cases showing a radiological response, CpG-28 showed modest activity on the 6-month PFS in this patient population, and the molecular or clinical characteristics of a subgroup of patients that could potentially benefit from such an approach remain to be defined.
Journal ArticleDOI
Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis
Madelon C. Vonk,Zora Marjanovic,F.H.J. van den Hoogen,Sarah Zohar,Anton Schattenberg,Willem E. Fibbe,Jérôme Larghero,Eliane Gluckman,Frank Preijers,A.P.J. van Dijk,J J Bax,P Roblot,P.L.C.M. van Riel,J.M. van Laar,Dominique Farge +14 more
TL;DR: It is confirmed that autologous HSCT in selected patients with severe diffuse cutaneous SSc results in sustained improvement of skin thickening and stabilisation of organ function up to 7 years after transplantation.